BJH - volume 12, issue 4, june 2021
B. De Moerloose MD, PhD, J. Philippé MD, PhD, M. Hofmans MD, T. Lammens PhD
Juvenile myelomonocytic leukaemia is a rare and aggressive clonal disease of early childhood for which hematopoietic stem cell transplantation remains the only curative option, albeit with a high relapse rate and many associated toxicities. Long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) have recently been implicated in a variety of biological processes, including haematopoiesis and receive much research attention as they possess features interesting for treatment, such as tissue specificity, low overall expression and easy targetability with RNAi or gene editing technology. Within this dissertation, we aimed at deciphering the lncRNA and circRNA transcriptome of JMML and use this knowledge to develop novel treatments.
(BELG J HEMATOL 2021;12(4):173-6)Read more
BJH - volume 12, issue 3, may 2021
J. Maertens MD, PhD, K. Lagrou PhD, PharmD, T. Mercier MD, PhD
Invasive mould infections such as invasive aspergillosis or mucormycosis remain an important infectious complication in haematology patients, especially in those undergoing intensive chemotherapy for acute myeloid leukaemia or undergoing allogeneic stem cell transplantation. An early diagnosis and timely initiation of antifungal therapy improves outcomes. In this thesis, we therefore looked at new possible diagnostic tools to aid in a rapid diagnosis, such as lateral flow assays, PCR tests, or a novel beta-D-glucan assay. Furthermore, we explored how we could get the maximum out of existing tests such as galactomannan, by optimising their use after therapy in an effort to assess the response to therapy.
(BELG J HEMATOL 2020;12(3):138-40)Read more
BJH - 2021, issue 2, march 2021
C. Lambert MD
In developing countries, the high rate of haemophilia-related mortality and morbidity is mainly caused by a lack of knowledge, underdiagnoses and very limited access to treatment. This work carried out in Côte d’Ivoire as a part of the World Federation of Hemophilia twinning program, aimed to evaluate the impact of non-substitutive strategies (not based on concentrates of coagulation factors) on the management of haemophilia. This project sought at developing and validating education materials to improve knowledge on haemophilia, implementing a self-physiotherapy program, and obtaining cross-cultural and validated tools to assess the quality of life of people with haemophilia. These initiatives were the starting point for haemophilia care in Côte d’Ivoire, by providing patients with low-cost measures and creating an environment favourable for the use of substitutive treatment issued from humanitarian aid. This thesis was defended at UCLouvain on September 01, 2020. The full manuscript of this these is available on dial.uclouvain.be.
(BELG J HEMATOL 2020;12(2):90-2)Read more
BJH - volume 11, issue 7, november 2020
dr. A. Delie MD, D. Breems MD, PhD, D. Selleslag MD, I. Moors MD, S. Anguille MD, PhD, S. Kennes MD, T. Kerre MD, PhD
In hyperleukocytic acute myeloid leukaemia (AML) the risk of leukostasis is high due to the rapid increase in WBC count and the size of the myeloid blasts. It is associated with poor prognosis due to an increased risk of early death and relapse. Immediate initiation of cytoreductive treatment is essential to improve outcome, but evidence to prefer hydroxyurea, leukapheresis, intensive chemotherapy (IC) or a combination treatment, is lacking. Therefore, we decided to investigate the current approach of hyperleukocytic AML in Belgium.
A brief questionnaire on the management of hyperleukocytic AML was sent to all Belgian centres currently treating AML with IC and was replied by ten centres. Four centres agreed to a more detailed retrospective analysis. All newly diagnosed AML patients presenting with hyperleukocytosis between January 2013 and April 2019 were included. Patient and disease characteristics were collected, as well as treatment choice and outcome parameters.
We included 121 patients with a median WBC count of 116,360/µL. Mortality at day 21 was 20% and overall mortality was 64% at a median follow-up of six months. Twenty percent received leukapheresis, which was started within 24 hours. There was no difference in age distribution, treatment intensity or time to start IC between patients receiving leukapheresis or not. Although the leukapheresis group had a more severe presentation with a higher median WBC and blast count and a worse performance status, there was no difference in response to therapy, early or long-term mortality. In a multivariate analysis, age at diagnosis and treatment modality (IC vs non-IC) were the only independent parameters that significantly affected early death.
Evidence on optimal treatment options in hyperleukocytic AML is lacking. We could not demonstrate any added value of leukapheresis. To improve the prognosis of this dramatic presentation, national or even European databases should be used to document and learn from the outcome of current practice.
(BELG J HEMATOL 2020;11(7):325-34)Read more
BJH - volume 11, issue 3, may 2020
C.M. Verfaillie MD, K. De Keersmaecker PhD, M. Delforge MD, PhD, N.G. Kint MD, PhD
Proteasome inhibitors (PIs) constitute one of the cornerstones of the treatment of multiple myeloma (MM), with bortezomib, carfilzomib and ixazomib being approved for clinical use. Due to the relatively recent introduction of PIs to clinical practice, many aspects of the pleiotropic effects of PIs still remain unexplored, particularly for the second-generation PIs carfilzomib and ixazomib. Since MM still remains incurable and many patients will eventually develop treatment-refractory disease, the search for validated biomarkers to predict treatment response is of great clinical importance. In the first aim of this project, we evaluated the effect of proteasome inhibitors on erythropoiesis. During the follow-up of MM patients treated with PIs in the first part of this project, we observed a consistent and highly significant increase in the reticulocyte count during treatment with carfilzomib-based regimens in patients with relapsed multiple myeloma. This observation was not made in a matched cohort of bortezomib-treated patients. In subsequent ex vivo experiments, we demonstrated that carfilzomib exposure significantly impaired terminal erythroid maturation, independent of erythroid commitment, expansion or differentiation. Our results therefore report the first pharmacologically induced delay in erythroid maturation as a mechanism for carfilzomib-induced reticulocytosis in patients with multiple myeloma. These findings might therefore lead to new therapeutic applications for carfilzomib in disorders of mature erythrocytes, such as sickle cell anaemia. In the second part of this project, we evaluated proteasome activity as a potential biomarker for PI drug sensitivity. For this purpose, we measured proteasome activity in primary myeloma cells, purified from the bone marrow of patients with MM. Baseline proteasome activity was not significantly different in myeloma cells derived from treatment-responsive or –refractory MM patients. The degree of proteasome inhibition by PIs was similar in both groups. As a result, the clinical applicability of proteasome activity as a biomarker for drug sensitivity in MM currently remains limited. Nevertheless, these data also suggest that drug sensitivity to PIs is in part proteasome-independent, indicating that our understanding of PI drug resistance should be further improved. In a follow-up project to the present thesis, we have designed several genome-wide screening experiments using CRISPR-Cas9 technology to gain novel insights in the mechanisms driving drug resistance to PIs in MM.
(BELG J HEMATOL 2020;11(3):133–5)Read more
BJH - volume 10, issue 2, march 2019
A. Jaspers MD, PhD, Y. Beguin MD, PhD
After haematopoietic stem cell transplantation (HCT), many patients present anaemia, which can persist for months due to an inadequate erythropoietin production for the degree of the anaemia. In this thesis, we performed two randomised studies with erythropoiesis-stimulating agents therapy after allogeneic (including myeloablative and non-myeloablative conditioning) and autologous transplantation. We showed a great efficacy of this growth factor to ensure full erythroid reconstitution when initiated soon after engraftment and not immediately after the transplant. Furthermore, as iron parameters are quite disturbed following HCT, we sought to study iron metabolism after HCT (which has not been much investigated), integrating the role of hepcidin, the key regulator in iron metabolism. Hence, we demonstrated that hepcidin levels prior to and following autologous HCT were influenced by iron stores and changes in erythropoietic activity.
(BELG J HEMATOL 2019;10(2):89–95)Read more
BJH - volume 9, issue 7, december 2018
dr. A. Delie MD, I. Moors MD, T. Kerre MD, PhD
Since several years, it has become clear that intermediate-risk acute myeloid leukaemia patients in an acceptable clinical condition can benefit from allogeneic stem cell transplantation thanks to the improvement in relapse free survival. This study retrospectively analysed the outcome of all intermediate-risk acute myeloid leukaemia patients treated with intensive chemotherapy at the Ghent University Hospital between 01-01-2013 and 30-04-2017 in an effort to determine the impact of a new in-hospital treatment guideline adopted in April 2015. This guideline recommends all intermediate-risk acute myeloid leukaemia patients who are fit for intensive therapy to proceed to allogeneic stem cell transplantation in first complete remission. Unfortunately, we could not demonstrate an improvement in the relapse free survival after implementation of the treatment guideline. Nevertheless, exploratory analysis of the entire group suggests a survival benefit from allogeneic stem cell transplantation, with significantly improved relapse free survival and a trend towards a better overall survival.
(BELG J HEMATOL 2018;9(7):285–9)Read more